Bio Plus Balance Sheet Health
Financial Health criteria checks 5/6
Bio Plus has a total shareholder equity of ₩149.8B and total debt of ₩54.2B, which brings its debt-to-equity ratio to 36.2%. Its total assets and total liabilities are ₩248.4B and ₩98.7B respectively. Bio Plus's EBIT is ₩16.1B making its interest coverage ratio -9.8. It has cash and short-term investments of ₩69.0B.
Key information
36.2%
Debt to equity ratio
₩54.21b
Debt
| Interest coverage ratio | -9.8x |
| Cash | ₩69.04b |
| Equity | ₩149.75b |
| Total liabilities | ₩98.67b |
| Total assets | ₩248.43b |
Recent financial health updates
No updates
Recent updates
Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return
Dec 15
Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit
Nov 23Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%
Jul 23The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence
Jul 05More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%
Jun 08Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings
Mar 26Financial Position Analysis
Short Term Liabilities: A099430's short term assets (₩96.1B) exceed its short term liabilities (₩94.4B).
Long Term Liabilities: A099430's short term assets (₩96.1B) exceed its long term liabilities (₩4.3B).
Debt to Equity History and Analysis
Debt Level: A099430 has more cash than its total debt.
Reducing Debt: A099430's debt to equity ratio has increased from 0% to 36.2% over the past 5 years.
Debt Coverage: A099430's debt is well covered by operating cash flow (53.6%).
Interest Coverage: A099430 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 16:52 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |
| Junghyun Kim | Kyobo Securities Co., Ltd |
| Jaehee Won | Shinhan Investment Corp. |